- cafead   Mar 27, 2023 at 10:22: AM
via Relmada Therapeutics announced it would make key changes to its clinical evaluation of REL-1017 as a possible add-on treatment for major depressive disorder (MDD), following two failed Phase III trials.
article source
article source